Compare CLRO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLRO | TCRT |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 7.8M |
| IPO Year | 2018 | 2025 |
| Metric | CLRO | TCRT |
|---|---|---|
| Price | $4.76 | $1.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.4M | 1.6M |
| Earning Date | 11-10-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,067,000.00 | $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $1.62 | $0.72 |
| 52 Week High | $16.50 | $4.50 |
| Indicator | CLRO | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 44.64 |
| Support Level | $3.32 | $1.61 |
| Resistance Level | $5.91 | $2.09 |
| Average True Range (ATR) | 0.87 | 0.17 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 37.91 | 10.16 |
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.